ArticleScientific reports2025
Uncovering the anti-cervical cancer mechanism of Ziyuglycoside I via integrated network pharmacology molecular docking and experimental validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
We aimed to conduct a systematic analysis of the multi-target regulatory mechanisms of Ziyu glycoside I (Ziyu I) in cervical cancer progression using network pharmacology and molecular docking techniques. Additionally, we validated our findings using cellular experiments and animal models. The PhamMapper database was used to identify drug targets for Ziyu I, while cervical cancer-related disease targets were obtained from the DisGeNET, DrugBank, GeneCards, and OMIM databases. In vitro, the effects of Ziyu I on the proliferation, migration, apoptosis, and cell cycle were assessed using cultured HeLa and SiHa cervical cancer cells. Network pharmacology analysis identified 68 potential targets of Ziyu I in cervical cancer. Molecular docking findings revealed that Ziyu I had a stable binding ability to MAPK1, MAPK8, and MAPK14, which are key targets in the MAPK signaling pathway. Cellular experiments revealed that Ziyu I significantly inhibited the proliferation and migration of cervical cancer cells and promoted apoptosis and cell cycle arrest. Finally, a nude mice-loaded tumor assay revealed that Ziyu I had significant anti-cervical cancer activity in vivo. Ziyu I inhibits cervical cancer progression through a multitarget regulatory network involving MAPK signaling pathway-mediated inhibition of cell proliferation and migration, apoptosis activation, and cell cycle arrest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.